These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 17599378

  • 1. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
    Nishimoto T, Ishikawa E, Anayama H, Hamajyo H, Nagai H, Hirakata M, Tozawa R.
    Toxicol Appl Pharmacol; 2007 Aug 15; 223(1):39-45. PubMed ID: 17599378
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
    Flint OP, Masters BA, Gregg RE, Durham SK.
    Toxicol Appl Pharmacol; 1997 Jul 15; 145(1):91-8. PubMed ID: 9221828
    [Abstract] [Full Text] [Related]

  • 3. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes.
    Nishimoto T, Tozawa R, Amano Y, Wada T, Imura Y, Sugiyama Y.
    Biochem Pharmacol; 2003 Dec 01; 66(11):2133-9. PubMed ID: 14609738
    [Abstract] [Full Text] [Related]

  • 4. Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions.
    Shiomi M, Yamada S, Amano Y, Nishimoto T, Ito T.
    Br J Pharmacol; 2008 Jul 01; 154(5):949-57. PubMed ID: 18587443
    [Abstract] [Full Text] [Related]

  • 5. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone.
    Johnson TE, Zhang X, Bleicher KB, Dysart G, Loughlin AF, Schaefer WH, Umbenhauer DR.
    Toxicol Appl Pharmacol; 2004 Nov 01; 200(3):237-50. PubMed ID: 15504460
    [Abstract] [Full Text] [Related]

  • 6. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
    Amin D, Rutledge RZ, Needle SN, Galczenski HF, Neuenschwander K, Scotese AC, Maguire MP, Bush RC, Hele DJ, Bilder GE, Perrone MH.
    J Pharmacol Exp Ther; 1997 May 01; 281(2):746-52. PubMed ID: 9152381
    [Abstract] [Full Text] [Related]

  • 7. The Guinea pig as a preclinical model for demonstrating the efficacy and safety of statins.
    Madsen CS, Janovitz E, Zhang R, Nguyen-Tran V, Ryan CS, Yin X, Monshizadegan H, Chang M, D'Arienzo C, Scheer S, Setters R, Search D, Chen X, Zhuang S, Kunselman L, Peters A, Harrity T, Apedo A, Huang C, Cuff CA, Kowala MC, Blanar MA, Sun CQ, Robl JA, Stein PD.
    J Pharmacol Exp Ther; 2008 Feb 01; 324(2):576-86. PubMed ID: 17986646
    [Abstract] [Full Text] [Related]

  • 8. [Myotoxicity and rhabdomyolisis due to statins].
    Banga JD.
    Ned Tijdschr Geneeskd; 2001 Dec 08; 145(49):2371-6. PubMed ID: 11770264
    [Abstract] [Full Text] [Related]

  • 9. Statin-induced myopathy: the two faces of Janus.
    Arora R, Liebo M, Maldonado F.
    J Cardiovasc Pharmacol Ther; 2006 Jun 08; 11(2):105-12. PubMed ID: 16891287
    [Abstract] [Full Text] [Related]

  • 10. Statin safety: lessons from new drug applications for marketed statins.
    Jacobson TA.
    Am J Cardiol; 2006 Apr 17; 97(8A):44C-51C. PubMed ID: 16581328
    [Abstract] [Full Text] [Related]

  • 11. Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia.
    Seiki S, Frishman WH.
    Cardiol Rev; 2009 Apr 17; 17(2):70-6. PubMed ID: 19367148
    [Abstract] [Full Text] [Related]

  • 12. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.
    Nishimoto T, Amano Y, Tozawa R, Ishikawa E, Imura Y, Yukimasa H, Sugiyama Y.
    Br J Pharmacol; 2003 Jul 17; 139(5):911-8. PubMed ID: 12839864
    [Abstract] [Full Text] [Related]

  • 13. Emerging lipid-lowering drugs: squalene synthase inhibitors.
    Elsayed RK, Evans JD.
    Expert Opin Emerg Drugs; 2008 Jun 17; 13(2):309-22. PubMed ID: 18537523
    [Abstract] [Full Text] [Related]

  • 14. Preventive effects of bicarbonate on cerivastatin-induced apoptosis.
    Kobayashi M, Kaido F, Kagawa T, Itagaki S, Hirano T, Iseki K.
    Int J Pharm; 2007 Aug 16; 341(1-2):181-8. PubMed ID: 17553641
    [Abstract] [Full Text] [Related]

  • 15. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Jamal SM, Eisenberg MJ, Christopoulos S.
    Am Heart J; 2004 Jun 16; 147(6):956-65. PubMed ID: 15199341
    [Abstract] [Full Text] [Related]

  • 16. Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemia.
    Burnett JR.
    Curr Opin Investig Drugs; 2006 Sep 16; 7(9):850-6. PubMed ID: 17002264
    [Abstract] [Full Text] [Related]

  • 17. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia.
    Amano Y, Nishimoto T, Tozawa Ri, Ishikawa E, Imura Y, Sugiyama Y.
    Eur J Pharmacol; 2003 Apr 11; 466(1-2):155-61. PubMed ID: 12679152
    [Abstract] [Full Text] [Related]

  • 18. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro.
    Skottheim IB, Gedde-Dahl A, Hejazifar S, Hoel K, Asberg A.
    Eur J Pharm Sci; 2008 Apr 23; 33(4-5):317-25. PubMed ID: 18294823
    [Abstract] [Full Text] [Related]

  • 19. Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy.
    Osaki Y, Nakagawa Y, Miyahara S, Iwasaki H, Ishii A, Matsuzaka T, Kobayashi K, Yatoh S, Takahashi A, Yahagi N, Suzuki H, Sone H, Ohashi K, Ishibashi S, Yamada N, Shimano H.
    Biochem Biophys Res Commun; 2015 Oct 23; 466(3):536-40. PubMed ID: 26381177
    [Abstract] [Full Text] [Related]

  • 20. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
    Evans M, Rees A.
    Drug Saf; 2002 Oct 23; 25(9):649-63. PubMed ID: 12137559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.